Tag Archive for: Merck

August kicked off with two FDA approvals—for Merck’s Ebola vaccine in kids and Taiho’s combination therapy for metastatic colorectal cancer—and another rejection for Mesoblast’s aGVHD treatment.

Today the company warned of a steeper earnings decline due to a slump in demand for materials used to produce pharmaceuticals and semiconductors, as its high-tech niche markets get drawn into a wider downturn.

The FDA has approved Jemperli as an add-on to chemotherapy for patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient or microsatellite instability-high.

The company posted better-than-expected second-quarter sales on Tuesday on strong demand for its two top-selling products, cancer immunotherapy Keytruda and human papillomavirus (HPV) vaccine Gardasil.

Two late-stage trial wins for Merck’s investigational pneumococcal vaccine V116 could make it a serious challenger to Pfizer’s Prevnar 20 in the space.

The study showed that the therapy was able to help clear all signs of tumor in patients compared to neo-adjuvant placebo plus chemotherapy.

Global recruitment for the trial has begun, with the first patients being enrolled in Australia, the companies said, adding that the study would take place in more than 25 countries around the world.

J&J, Merck and Pfizer are the subjects of a House Judiciary Committee investigation for their alleged participation in a government-sanctioned censorship campaign during the COVID-19 pandemic.

Late-stage study suggests Merck’s Keytruda is a promising treatment candidate in newly diagnosed patients with locally advanced cervical cancer, inducing better progression-free survival.

Following its initial lawsuit last month, Merck has now requested that a federal judge rule on its Inflation Reduction Act case against the Biden administration without a trial.